secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2026-01-22T23:59:59+00:00
Accession:  0001628280-26-002982
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q4 adj EPS $1.50 (+12% YoY); FY2025 revenue $44.3B; FY2026 adj EPS guide $5.55–$5.80
--------------------------------------------------------------------------------

- Q4 GAAP EPS $1.01, adjusted EPS $1.50 (+12% YoY); revenue $11.46B (+4.4% reported, +3.8% ex-COVID).
- FY2025 adjusted EPS $5.15 (+10% YoY); revenue $44.3B (+5.7% reported, +6.7% ex-COVID).
- FY2026 guidance: organic sales growth 6.5%-7.5%; adjusted EPS $5.55-$5.80 (midpoint +10%).
- Medical Devices sales +12.3% reported (+10.4% organic); CGM sales $2.0B up 15% reported.
- Agreed to acquire Exact Sciences (cancer diagnostics); close expected Q2 2026. FDA OK for Volt PFA System.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828026002982/0001628280-26-002982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828026002982/abt-20260122.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-002982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer